

**A Phase III multicentre randomised clinical trial of R-CHOP14 vs
R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma**

Patient initials		Date of birth	(dd/mm/yyyy)
Centre		Consultant	
Trial number		Sex	1=M, 2=F

Please complete at 3, 6, 9, 12, 18 and 24 months after completion of protocol treatment, and annually thereafter. Return to Lymphoma Trials Office, 90 Tottenham Court Road, London W1T 4TJ, within 6 weeks of assessment

Follow up form (page 1 of 1)

Patient status

Date of Assessment _____ (dd/mm/yyyy)

- 1=Alive without progression
 2=Alive with progression/relapse Please complete disease progression form
 3=Dead Please complete death form

Any further anti cancer therapy given (since last follow up) 0= No, 1=Yes

If yes, what treatment given? _____

Reason for therapy a) Progression
 b) Other please specify _____

Form completed by: _____	Date of completion: _____
Signature: _____	

**A Phase III multicentre randomised clinical trial of R-CHOP14 vs
R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma**

Patient initials		Date of birth	(dd/mm/yyyy)
Centre		Consultant	
Trial number		Sex	1=M, 2=F

Complete after any disease progression. Please return to Lymphoma Trials Office, 90 Tottenham Court Road, London W1T 4TJ as soon as possible after confirmation of disease progression.

Disease progression form (page 1 of 3)

Date of first progression (dd/mm/yyyy)	
--	--

Please specify nature of disease progression (1=Yes, 0=No)

Development of new lymph nodes/mass	
≥ 50% increase in size of lymph nodes/mass	
Enlarging liver or spleen	
The development of B symptoms or severe pruritis	
Reappearance of bone marrow disease	

**A Phase III multicentre randomised clinical trial of R-CHOP14 vs
R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma**

Patient initials		Date of birth	(dd/mm/yyyy)	
Centre		Consultant		
Trial number		Sex	1=M, 2=F	

Disease progression form (page 2 of 3)

Sites of Nodal Disease

Site	Involved Y=Involved N= not involved	Investigation 1=clinical 2=x-ray 3=CT scan 4=other	Measurable M=measurable E=evaluable	Size Bidimensional measurements (mm x mm)
Left cervical				
Right cervical				
Left supraclavicular				
Right supraclavicular				
Waldeyer's ring				
Left axillary				
Right axillary				
Paratracheal				
Mediastinal				
Hilar				
Retrocrural				
Para-aortic				
Coeliac axis				
Mesenteric				
Splenic				
Portal				
Left iliac				
Right iliac				
Left inguinal				
Right inguinal				
Left femoral				
Right femoral				
Other, specify				
Other, specify				
Other, specify				
Other, specify				

**A Phase III multicentre randomised clinical trial of R-CHOP14 vs
R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma**

Patient initials		Date of birth	(dd/mm/yyyy)	
Centre		Consultant		
Trial number		Sex	1=M, 2=F	

Disease progression form (page 3 of 3)

Sites of Extranodal Disease

Site	Involved Y=Involved N= not involved	Investigation 1=clinical 2=x-ray 3=CT scan 4=other	Measurable M=measurable E=evaluabe	Size Bidimensional measurements (mm x mm)
Spleen				
Liver				
Lungs				
Bone marrow				
Kidney				
Pericardium				
Pleura				
Skin				
Testis				
Other, specify				
Other, specify				

Form completed by: _____ Date of completion: _____

Signature: _____

**A Phase III multicentre randomised clinical trial of R-CHOP14 vs
R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma**

Patient initials		Date of birth	(dd/mm/yyyy)
Centre		Consultant	
Trial number		Sex	1=M, 2=F

Please complete at the time of the patient's death. Please return as soon as possible to the Lymphoma Trials Office, 90 Tottenham Court Road, London W1T 4TJ.

Death form (1 of 1)

Date of death (dd/mm/yyyy)	
----------------------------	--

Cause of Death

1=Non-Hodgkin's lymphoma

2=Treatment related toxicity

3=Secondary malignancy, please specify

Date confirmed (dd/mm/yyyy)

Type of malignancy

4=Cardiac death

5=Other, please specify

Form completed by: _____ Date of completion: _____

Signature: _____